AR100790A2 - COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS - Google Patents

COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS

Info

Publication number
AR100790A2
AR100790A2 ARP150101838A ARP150101838A AR100790A2 AR 100790 A2 AR100790 A2 AR 100790A2 AR P150101838 A ARP150101838 A AR P150101838A AR P150101838 A ARP150101838 A AR P150101838A AR 100790 A2 AR100790 A2 AR 100790A2
Authority
AR
Argentina
Prior art keywords
lactames
inhibitors
active
heterocyclic compounds
ceftazidime
Prior art date
Application number
ARP150101838A
Other languages
English (en)
Original Assignee
Astra Zeneca Holding France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100790(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Zeneca Holding France filed Critical Astra Zeneca Holding France
Publication of AR100790A2 publication Critical patent/AR100790A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que comprenden compuestos de fórmula (1), y sus sales farmacéuticamente aceptables, en la preparación de un medicamento destinado a inhibir la producción de b-lactamasas por bacterias patógenas. Reivindicación 2: Una composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque la cefalosporina está seleccionada a partir de cefotaxima, cefpiroma y ceftazidima. Reivindicación 3: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque el inhibidor de b-lactamasa es la sal de sodio de trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo[3.2.1]octano-2-carboxamida, y la cefalosporina es ceftazidima.
ARP150101838A 2002-01-28 2015-06-10 COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS AR100790A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
AR100790A2 true AR100790A2 (es) 2016-11-02

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030100226A AR038234A1 (es) 2002-01-28 2003-01-27 Compuestos heterociclicos, activos como inhibidores de beta-lactamasas
ARP150101838A AR100790A2 (es) 2002-01-28 2015-06-10 COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030100226A AR038234A1 (es) 2002-01-28 2003-01-27 Compuestos heterociclicos, activos como inhibidores de beta-lactamasas

Country Status (45)

Country Link
US (4) US7612087B2 (es)
EP (2) EP2279737B1 (es)
JP (1) JP4472346B2 (es)
KR (1) KR100979079B1 (es)
CN (3) CN100482225C (es)
AR (2) AR038234A1 (es)
AT (1) ATE484281T1 (es)
AU (1) AU2003214335B2 (es)
BE (1) BE2016C069I2 (es)
BR (1) BRPI0307267B8 (es)
CA (1) CA2474043C (es)
CL (1) CL2011000009A1 (es)
CO (1) CO5601014A2 (es)
CR (2) CR7387A (es)
CY (3) CY1111061T1 (es)
DE (1) DE60334527D1 (es)
DK (2) DK2279737T3 (es)
EA (1) EA007220B1 (es)
EC (1) ECSP045193A (es)
ES (2) ES2401855T3 (es)
FR (1) FR2835186B1 (es)
HK (2) HK1077205A1 (es)
HR (1) HRP20040686B1 (es)
HU (1) HUS1600055I1 (es)
IL (1) IL163167A (es)
JO (1) JO2646B1 (es)
LT (1) LTC1480644I2 (es)
MA (1) MA26351A1 (es)
MX (1) MXPA04006621A (es)
MY (1) MY140638A (es)
NL (1) NL300847I2 (es)
NO (2) NO335195B1 (es)
NZ (1) NZ533936A (es)
OA (1) OA12761A (es)
PE (1) PE20030969A1 (es)
PL (1) PL220725B1 (es)
PT (2) PT2279737E (es)
RS (1) RS52137B (es)
SI (2) SI1480644T1 (es)
TN (1) TNSN04137A1 (es)
TW (1) TWI293071B (es)
UA (1) UA80271C2 (es)
UY (1) UY27626A1 (es)
WO (1) WO2003063864A2 (es)
ZA (1) ZA200405607B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
WO2007063552A1 (en) * 2005-12-02 2007-06-07 Lupin Limited Stable taste masked formulations of cephalosporins
SI1965798T1 (sl) * 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
CA2667816A1 (en) * 2006-10-23 2008-05-02 Irm Llc Compositions and methods for inhibiting cathepsin proteases
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
UA101966C2 (en) * 2008-01-18 2013-05-27 Мерк Шарп Енд Доме Корп. Beta-lactamase inhibitors
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5501983B2 (ja) * 2008-06-11 2014-05-28 塩野義製薬株式会社 オキシカルバモイル化合物およびその使用
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
KR102087313B1 (ko) 2010-08-10 2020-03-11 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 제조방법
WO2012086241A1 (ja) * 2010-12-22 2012-06-28 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
AU2012270051B2 (en) 2011-06-17 2016-12-22 Pfizer Anti-Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CA2833241C (en) * 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
MX349827B (es) * 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
BR112014029368B1 (pt) * 2012-05-30 2020-10-27 Meiji Seika Pharma Co., Ltd inibidor de beta-lactamase e processo para preparar o mesmo
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20150203503A1 (en) * 2012-08-25 2015-07-23 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941247A4 (en) 2013-01-04 2017-02-08 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) 2013-01-04 2014-07-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
EP3050883B1 (en) 2013-09-24 2020-04-22 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivatives and intermediates
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BR122022016622B1 (pt) 2013-10-08 2023-11-07 Meiji Seika Pharma Co., Ltd. Formas cristalinas de derivado de diazabiciclo-octano, seus processos de produção e uso das mesmas
EP3107539A1 (en) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
DK3140310T3 (da) 2014-05-05 2019-10-21 Rempex Pharmaceuticals Inc Syntese af boronatsalte og brug deraf
CN106459096B (zh) 2014-05-19 2019-03-08 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
PT3221313T (pt) * 2014-11-17 2019-04-15 Entasis Therapeutics Ltd Terapia combinada para tratamento de infecções bacterianas resistentes
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TWI754613B (zh) * 2015-05-07 2022-02-11 法商木塔比利斯公司 雜環化合物及其用於預防或治療細菌感染之用途
JP2018515481A (ja) * 2015-09-16 2018-06-14 シュアンチュー ファーマ カンパニー，リミティド β−ラクタマーゼ阻害剤とその利用
TW201725205A (zh) 2015-10-02 2017-07-16 樂高化學生物科學股份有限公司 用於抑制β-內醯胺酶之組合物及方法
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
SG11201811549UA (en) 2016-06-30 2019-01-30 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
MX2021010077A (es) 2016-09-16 2022-05-23 Entasis Therapeutics Ltd Compuestos inhibidores de beta-lactamasa.
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
TW201831482A (zh) 2017-02-06 2018-09-01 法商木塔比利斯公司 新穎雜環化合物及其預防或治療細菌感染之用途
SI3630111T1 (sl) 2017-05-08 2022-05-31 Entasis Therapeutics, Inc. Spojine in postopki za zdravljenje bakterijskih okužb
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
US20230365561A1 (en) * 2020-09-01 2023-11-16 Ningxia Academy Of Agricul Ture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
CN116375706A (zh) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
DK0480939T3 (da) 1989-06-09 1995-07-10 Upjohn Co Heterocycliske aminer med virkning på centralnervesystemet
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
ES2269528T3 (es) 1993-09-29 2007-04-01 Nabi Nucleosidos y nucleotidos con un anillo heterociclico.
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
HUP9900973A3 (en) * 1996-01-03 2000-04-28 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline with antibacterial activity, pharmaceutical compns. contg. them and process for preparing the said compds.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
CA2327695A1 (en) 1998-04-08 1999-10-21 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CO5160344A1 (es) 1998-12-18 2002-05-30 Schering Corp Inhibidores de transferasa de proteina farnesilo
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMIN DERIVATIVES
EP1288216A1 (en) 2000-04-18 2003-03-05 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
DE60220057T2 (de) 2001-02-22 2008-01-10 School Of Pharmacy, University Of London Indoline und Tetrahydrochinoline als Prodrugs zur Tumorbehandlung
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
NO2016024I1 (no) 2016-12-15
TNSN04137A1 (fr) 2007-03-12
PL371601A1 (en) 2005-06-27
HK1077205A1 (en) 2006-02-10
CY2016042I2 (el) 2017-03-15
HUS1600055I1 (hu) 2017-01-30
WO2003063864A2 (fr) 2003-08-07
CY1114417T1 (el) 2016-08-31
DK2279737T3 (da) 2013-02-11
YU65804A (sh) 2006-08-17
ES2401855T3 (es) 2013-04-25
BRPI0307267B1 (pt) 2016-02-10
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
WO2003063864A3 (fr) 2004-03-11
LTPA2016037I1 (lt) 2017-01-10
EP1480644B1 (fr) 2010-10-13
CY1111061T1 (el) 2015-06-11
EA007220B1 (ru) 2006-08-25
CA2474043C (fr) 2011-08-02
PT1480644E (pt) 2011-01-17
CN100563653C (zh) 2009-12-02
JP4472346B2 (ja) 2010-06-02
CR7387A (es) 2010-10-25
MXPA04006621A (es) 2004-10-04
NL300847I2 (es) 2017-01-03
NZ533936A (en) 2007-05-31
ZA200405607B (en) 2005-09-28
OA12761A (fr) 2006-07-04
LTC1480644I2 (lt) 2018-09-10
DK1480644T3 (da) 2011-01-24
JP2005523897A (ja) 2005-08-11
ATE484281T1 (de) 2010-10-15
PL220725B1 (pl) 2015-12-31
CL2011000009A1 (es) 2011-03-25
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
US20110245254A1 (en) 2011-10-06
KR20040081473A (ko) 2004-09-21
BRPI0307267B8 (pt) 2021-05-25
DE60334527D1 (de) 2010-11-25
TWI293071B (en) 2008-02-01
NO335195B1 (no) 2014-10-20
US20090215747A1 (en) 2009-08-27
KR100979079B1 (ko) 2010-08-31
HK1105864A1 (en) 2008-02-29
BR0307267A (pt) 2004-12-07
CA2474043A1 (fr) 2003-08-07
CY2016042I1 (el) 2017-03-15
HRP20040686A2 (en) 2004-12-31
EA200400981A1 (ru) 2005-02-24
CN1994301A (zh) 2007-07-11
UY27626A1 (es) 2003-08-29
UA80271C2 (uk) 2007-09-10
SI1480644T1 (sl) 2011-03-31
ES2356813T3 (es) 2011-04-13
EP2279737A1 (fr) 2011-02-02
US20050020572A1 (en) 2005-01-27
NO2016024I2 (no) 2016-12-15
CO5601014A2 (es) 2006-01-31
MA26351A1 (fr) 2004-10-01
FR2835186B1 (fr) 2006-10-20
AR038234A1 (es) 2005-01-05
PT2279737E (pt) 2013-02-01
CN100482225C (zh) 2009-04-29
CN101406471A (zh) 2009-04-15
ECSP045193A (es) 2004-08-27
HRP20040686B1 (hr) 2013-02-28
NO20043587L (no) 2004-08-27
FR2835186A1 (fr) 2003-08-01
US7612087B2 (en) 2009-11-03
JO2646B1 (en) 2012-06-17
RS52137B (en) 2012-08-31
CN1655781A (zh) 2005-08-17
US20100048528A1 (en) 2010-02-25
MY140638A (en) 2010-01-15
AU2003214335B2 (en) 2007-04-05
EP2279737B1 (fr) 2012-10-31
SI2279737T1 (sl) 2013-07-31
BE2016C069I2 (es) 2022-05-17
IL163167A (en) 2010-04-15

Similar Documents

Publication Publication Date Title
AR100790A2 (es) COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
CU20110217A7 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
PA8591701A1 (es) Derivados de pirrolopirimidina
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
SG151286A1 (en) 5-substituted-2-phenylamino-benzamide as mek inhibitor
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
BR0313407A (pt) Novo uso de derivados de benzotiazol
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
PE20090445A1 (es) Inhibidores de produccion de beta amiloide
ATE432262T1 (de) Pyrazolphenylderivate als ppar-aktivatoren
AR050101A1 (es) Oxazolidinonas que contienen oxindoles como agentes antibacterianos.
DOP2023000028A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
UY26844A1 (es) Nuevos derivados de la pirrolidona
BR122015020406B8 (pt) uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
AR039704A1 (es) Difluorotioacetamidas de oxazolidinonas con un sustituyente glicoloilpiperazina
TH62584A (th) สารละลายเมลอกซิแคมที่เสถียรชนิดเข้มข้นสูงสำหรับการฉีดแบบไม่ใช้เข็ม
AR054491A1 (es) Uso farmaceutico de una 1-(3-clorofenil)-3-alquilpiperazina
TN2011000592A1 (en) Substituted aminopropionic derivatives as neprilysin inhibitors
ECSP982501A (es) Derivados de eritromicina
UA107092C2 (uk) Заміщені похідні карбамоїлметиламінооцтової кислоти як інгібітори nep